COVID-19 vaccine developed by AstraZeneca and the University of Oxford are set to resume after a six-day pause due to “potentially unexplained illness” in the United Kingdom.An independent safety review was conducted Sept.
6 during what was referred to as a “routine action” to maintain the “integrity of the trials.” It concluded on Saturday.In a release sent to Global News, Oxford University said the study vaccines had been administered to some 18,000 patients as part of the trial.
AstraZeneca pauses COVID-19 vaccine trial after unexplained illness in U.K. “In large trials such as this, it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety,” the release.